Literature DB >> 14500687

Antagonistic effects of TNF-alpha on TGF-beta signaling through down-regulation of TGF-beta receptor type II in human dermal fibroblasts.

Kenichi Yamane1, Hironobu Ihn, Yoshihide Asano, Masatoshi Jinnin, Kunihiko Tamaki.   

Abstract

Transforming growth factor-beta stimulates the production of the extracellular matrix, whereas TNF-alpha has antifibrotic activity. Understanding the molecular mechanism underlying the antagonistic activities of TNF-alpha against TGF-beta is critical in the context of tissue repair and maintenance of tissue homeostasis. In the present study, we demonstrated a novel mechanism by which TNF-alpha blocks TGF-beta-induced gene and signaling pathways in human dermal fibroblasts. We showed that TNF-alpha prevents TGF-beta-induced gene trans activation, such as alpha2(I) collagen or tissue inhibitor of metalloproteinases 1, and TGF-beta signaling pathways, such as Smad3, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinases, without inducing levels of inhibitory Smad7 in human dermal fibroblasts. TNF-alpha down-regulates the expression of type II TGF-beta receptor (TbetaRII) proteins, but not type I TGF-beta receptor (TbetaRI), in human dermal fibroblasts. However, neither TbetaRII mRNA nor TbetaRII promoter activity was decreased by TNF-alpha. TNF-alpha-mediated decrease of TbetaRII protein expression was not inhibited by the treatment of fibroblasts with either a selective inhibitor of I-kappaB-alpha phosphorylation, BAY 11-7082, or a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor, PD98059. Calpain inhibitor I (ALLN), a protease inhibitor, inhibits TNF-alpha-mediated down-regulation of TbetaRII. We found that TNF-alpha triggered down-regulation of TbetaRII, leading to desensitization of human dermal fibroblasts toward TGF-beta. Furthermore, these events seemed to cause a dramatic down-regulation of alpha2(I) collagen and tissue inhibitor of metalloproteinases 1 in systemic sclerosis fibroblasts. These results indicated that TNF-alpha impaired the response of the cells to TGF-beta by regulating the turnover of TbetaRII.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500687     DOI: 10.4049/jimmunol.171.7.3855

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Candidate genes for colour and vision exhibit signals of selection across the pied flycatcher (Ficedula hypoleuca) breeding range.

Authors:  P K Lehtonen; T Laaksonen; A V Artemyev; E Belskii; P R Berg; C Both; L Buggiotti; S Bureš; M D Burgess; A V Bushuev; I Krams; J Moreno; M Mägi; A Nord; J Potti; P-A Ravussin; P M Sirkiä; G-P Sætre; W Winkel; C R Primmer
Journal:  Heredity (Edinb)       Date:  2011-10-26       Impact factor: 3.821

Review 2.  Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab.

Authors:  Y Allanore; G Devos-François; C Caramella; P Boumier; V Jounieaux; A Kahan
Journal:  Ann Rheum Dis       Date:  2006-06       Impact factor: 19.103

3.  Loss of tumor necrosis factor alpha potentiates transforming growth factor beta-mediated pathogenic tissue response during wound healing.

Authors:  Shizuya Saika; Kazuo Ikeda; Osamu Yamanaka; Kathleen C Flanders; Yuka Okada; Takeshi Miyamoto; Ai Kitano; Akira Ooshima; Yuji Nakajima; Yoshitaka Ohnishi; Winston W-Y Kao
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

Review 4.  Recent advances on pathogenesis and therapies in systemic sclerosis.

Authors:  Norihito Yazawa; Manabu Fujimoto; Kunihiko Tamaki
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

5.  Up regulated expression of tumour necrosis factor {alpha} converting enzyme in peripheral monocytes of patients with early systemic sclerosis.

Authors:  T Bohgaki; Y Amasaki; N Nishimura; M Bohgaki; Y Yamashita; M Nishio; K-I Sawada; S Jodo; T Atsumi; T Koike
Journal:  Ann Rheum Dis       Date:  2005-08       Impact factor: 19.103

6.  Thrombospondin 1 acts as a strong promoter of transforming growth factor beta effects via two distinct mechanisms in hepatic stellate cells.

Authors:  K Breitkopf; I Sawitza; J H Westhoff; L Wickert; S Dooley; A M Gressner
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

Review 7.  Scleroderma, fibroblasts, signaling, and excessive extracellular matrix.

Authors:  Hironobu Ihn
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

8.  The p65 subunit of NF-κB inhibits COL1A1 gene transcription in human dermal and scleroderma fibroblasts through its recruitment on promoter by protein interaction with transcriptional activators (c-Krox, Sp1, and Sp3).

Authors:  Gallic Beauchef; Nicolas Bigot; Magdalini Kypriotou; Emmanuelle Renard; Benoît Porée; Russell Widom; Anne Dompmartin-Blanchere; Thierry Oddos; François-Xavier Maquart; Magali Demoor; Karim Boumediene; Philippe Galera
Journal:  J Biol Chem       Date:  2011-12-02       Impact factor: 5.157

9.  Pamidronate infusion in patients with systemic sclerosis results in changes in blood mononuclear cell cytokine profiles.

Authors:  L D Carbone; K J Warrington; K D Barrow; M Pugazhenthi; M A Watsky; G Somes; J Ingels; A E Postlethwaite
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

Review 10.  Progranulin: A key player in autoimmune diseases.

Authors:  Jinlong Jian; Guangfei Li; Aubryanna Hettinghouse; Chuanju Liu
Journal:  Cytokine       Date:  2016-08-12       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.